Acute myeloid leukemia after infliximab: A case report

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 999-1000

  Kemta Lekpa, Fernando ^a   Zahra, Kmira ^a   Pautas, Cécile ^a   Maury, Sébastien ^a   Chevalier, Xavier ^a   Claudepierre, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Ankylosing spondylitis; Infliximab; TNF antagonists

Indexed keywords

ANTHRACYCLINE; CD33 ANTIGEN; CD34 ANTIGEN; CYTARABINE; HLA DR ANTIGEN; INFLIXIMAB; MICROSOMAL AMINOPEPTIDASE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; ANKYLOSING SPONDYLITIS; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW BIOPSY; CANCER RISK; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PHARYNGITIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76649100095     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. BROWN SL, GREENE MH, GERSHON SK et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
2. GEBOREK P, BLADSTRÖM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
3. ALCAÍN G, ANDRADE RJ, QUEIPO DE LLANO MP, MORENO MJ, GARCÍA-CORTÉS M, FRANQUELO E: Acute leukemia after infliximab therapy. Am J Gastroenterol 2003; 98: 2577.
4. BAKLAND G, NOSSENT H: Acute myelogenous leukaemia following etanercept therapy. Rheumatology 2003; 42: 900-1.
5. BACHMEYER C, THIOLIÈRE BN KHOSROTEHRANI K, CATTAN E: Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2007; 56: 169-70.
6. NAIR B, RAVAL G, MAHTA P: TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007; 82: 1022-4.
7. SABA NS, KOSSEIFI SG, CHARAF EA, HAMMAD AN: Adalimumab-induced acute myelogenic leukemia. South Med J 2008; 101: 1261-2.
8. BIANCONE L, ORLANDO A, KOHN A et al.: Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006; 55: 228-33.
9. ZOCHLING J, BRAUN J: Mortality in ankylosing spondylitis. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S80-4.
10. TSIMBERIDOU AM, THOMAS D, O'BRIEN S et al.: Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 2002; 50: 237-42.
11. + myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-κB activation. J Immunol 1999; 163: 3106-15.
12. TSIMBERIDOU AM, ESTEY E, WEN S et al.: The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113: 1605-13.